Friday, November 20, 2026

Argenx SE Stock 29.53% Up Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Argenx SE Stock 29.53% Up Today

(VIANEWS) - The NASDAQ ended the session with argenx SE rising 29.53% to $491.01 on Monday, after two successive sessions in a row of gains. NASDAQ jumped 0.93% to $14,244.95, following the last session's downward trend on what was a somewhat up trend trading session today.

argenx SE's last close was $379.08, 10.59% under its 52-week high of $423.99.

About argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, argenx SE has a trailing twelve months EPS of $-9.4.

Volatility

argenx SE's last week, last month's, and last quarter's current intraday variation average was a negative 0.49%, a negative 0.23%, and a positive 1.11%.

argenx SE's highest amplitude of average volatility was 1.80% (last week), 1.22% (last month), and 1.11% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, argenx SE's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for argenx SE is 1483010 which is 569.06% above its average volume of 221654.

Moving Average

argenx SE's worth is way higher than its 50-day moving average of $395.72 and way above its 200-day moving average of $378.70.

More news about argenx SE (ARGX).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 17 Jul 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.